LivaNova (NASDAQ:LIVN) Downgraded to Buy Rating by StockNews.com

LivaNova (NASDAQ:LIVN) was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Wednesday.

Several other equities analysts also recently weighed in on the company. Needham & Company LLC cut their target price on LivaNova from $75.00 to $64.00 and set a “buy” rating on the stock in a research report on Wednesday. Robert W. Baird lifted their price objective on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Mizuho reduced their target price on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a research note on Wednesday. Wolfe Research lowered shares of LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday. Finally, Stifel Nicolaus cut their price target on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $64.20.

LivaNova Trading Down 1.3 %

LIVN opened at $40.93 on Wednesday. The stock has a 50-day moving average of $47.52 and a 200 day moving average of $49.50. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. LivaNova has a 12 month low of $40.37 and a 12 month high of $64.47. The firm has a market cap of $2.22 billion, a P/E ratio of 97.45 and a beta of 1.00.

Insider Activity

In related news, Director Francesco Bianchi sold 1,250 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the transaction, the director now owns 7,522 shares of the company’s stock, valued at $383,546.78. This trade represents a 14.25 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On LivaNova

A number of hedge funds have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. raised its stake in shares of LivaNova by 17.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock valued at $70,000 after acquiring an additional 219 shares in the last quarter. Sterling Capital Management LLC increased its holdings in LivaNova by 800.6% during the 4th quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock worth $75,000 after purchasing an additional 1,441 shares during the period. Central Pacific Bank Trust Division raised its position in LivaNova by 21.2% during the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock valued at $191,000 after purchasing an additional 720 shares in the last quarter. Vestcor Inc purchased a new stake in shares of LivaNova in the 4th quarter worth $204,000. Finally, Optimize Financial Inc bought a new position in shares of LivaNova during the 4th quarter worth $208,000. 97.64% of the stock is currently owned by institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.